

IsoRay, Inc.
Form 10-Q
May 04, 2018

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2018

or

Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission File No. 001-33407

ISORAY, INC.

(Exact name of registrant as specified in its charter)

Minnesota 41-1458152
(State or other jurisdiction of incorporation or (I.R.S. Employer
organization) Identification No.)

350 Hills St., Suite 106, Richland, Washington 99354
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (509) 375-1202

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Edgar Filing: IsoRay, Inc. - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-accelerated filer

Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No

Number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date:

| <u>Class</u> | <u>Outstanding as of May 2, 2018</u> |
|---------------------------------|--------------------------------------|
| Common stock, \$0.001 par value | 55,100,229 |

Table of Contents

ISORAY, INC.

Table of Contents

PART I FINANCIAL INFORMATION

| | | |
|--------|---|---|
| Item 1 | <u>Consolidated Unaudited Financial Statements</u> | 1 |
| | <u>Consolidated Balance Sheets</u> | 1 |
| | <u>Consolidated Statements of Operations (Unaudited)</u> | 2 |
| | <u>Consolidated Statements of Cash Flows (Unaudited)</u> | 3 |
| | <u>Notes to the Consolidated Unaudited Financial Statements</u> | 4 |

| | | |
|--------|--|----|
| Item 2 | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 11 |
|--------|--|----|

| | | |
|--------|---|----|
| Item 3 | <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 17 |
|--------|---|----|

| | | |
|--------|--------------------------------|----|
| Item 4 | <u>Controls and Procedures</u> | 17 |
|--------|--------------------------------|----|

PART II OTHER INFORMATION

| | | |
|--------|--------------------------|----|
| Item 1 | <u>Legal Proceedings</u> | 18 |
|--------|--------------------------|----|

| | | |
|---------|---------------------|----|
| Item 1A | <u>Risk Factors</u> | 18 |
|---------|---------------------|----|

| | | |
|--------|--|----|
| Item 2 | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 19 |
|--------|--|----|

| | | |
|--------|--|----|
| Item 3 | <u>Defaults Upon Senior Securities</u> | 19 |
|--------|--|----|

| | | |
|--------|--------------------------------|----|
| Item 4 | <u>Mine Safety Disclosures</u> | 19 |
|--------|--------------------------------|----|

| | | |
|--------|--------------------------|----|
| Item 5 | <u>Other Information</u> | 19 |
|--------|--------------------------|----|

| | | |
|--------|-----------------|----|
| Item 6 | <u>Exhibits</u> | 19 |
|--------|-----------------|----|

| | | |
|--|-------------------|----|
| | <u>Signatures</u> | 20 |
|--|-------------------|----|

Table of Contents**PART I – FINANCIAL INFORMATION****ITEM 1 – FINANCIAL STATEMENTS****IsoRay, Inc. and Subsidiaries
Consolidated Balance Sheets
(In thousands, except shares)**

| | March 31, 2018 | June 30, 2017 |
|--|---------------------------|--------------------------|
| | (unaudited) | |
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 2,365 | \$5,932 |
| Certificates of deposit (Note 3) | 2,150 | 3,039 |
| Accounts receivable, net of allowance for doubtful accounts of \$26 and \$26, respectively | 970 | 726 |
| Inventory | 458 | 323 |
| Prepaid expenses and other current assets | 382 | 271 |
| Total current assets | 6,325 | 10,291 |
| Property and equipment, net | 1,229 | 1,054 |
| Restricted cash | 181 | 181 |
| Inventory, non-current | 395 | 513 |
| Other assets, net of accumulated amortization | 192 | 230 |
| Total assets | \$ 8,322 | \$12,269 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | |
| Current liabilities: | | |
| Accounts payable and accrued expenses | \$ 773 | \$630 |
| Accrued protocol expense | 77 | 75 |
| Accrued radioactive waste disposal | 28 | 125 |
| Accrued payroll and related taxes | 105 | 138 |
| Accrued vacation | 140 | 138 |
| Total current liabilities | 1,123 | 1,106 |
| Long-term liabilities: | | |
| Asset retirement obligation | 583 | 561 |

Edgar Filing: IsoRay, Inc. - Form 10-Q

| | | |
|--|-----------|----------|
| Total liabilities | 1,706 | 1,667 |
| Commitments and contingencies (Note 8) | | |
| Shareholders' equity: | | |
| Preferred stock, \$.001 par value; 7,001,671 shares authorized: | | |
| Series A: 1,000,000 shares allocated; no shares issued and outstanding | - | - |
| Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding | - | - |
| Series C: 1,000,000 shares allocated; no shares issued and outstanding | - | - |
| Series D: 1,671 shares allocated; no shares issued and outstanding | - | - |
| Common stock, \$.001 par value; 192,998,329 shares authorized; 55,100,229 and 55,017,419 shares issued and outstanding | 55 | 55 |
| Additional paid-in capital | 83,507 | 83,151 |
| Accumulated deficit | (76,946) | (72,604) |
| Total shareholders' equity | 6,616 | 10,602 |
| Total liabilities and shareholders' equity | \$ 8,322 | \$12,269 |

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

IsoRay, Inc. and Subsidiaries
Consolidated Statements of Operations (Unaudited)
(Dollars and shares in thousands, except for per-share amounts)

| | Three months ended March 31, 2018 | | Nine months ended March 31, 2017 | |
|---|--|-------------|---|-------------|
| | 2018 | 2017 | 2018 | 2017 |
| Product sales, net | \$1,573 | \$1,282 | \$4,320 | \$3,391 |
| Cost of product sales | 964 | 989 | 2,915 | 3,051 |
| Gross profit | 609 | 293 | 1,405 | 340 |
| Operating expenses: | | | | |
| Research and development | | | | |
| Proprietary research and development | 317 | 166 | 914 | 488 |
| Collaboration arrangement, net of reimbursement (Note 8) | 156 | 161 | 260 | 161 |
| Total research and development | 473 | 327 | 1,174 | 649 |
| Sales and marketing | 692 | 530 | 1,980 | 1,550 |
| General and administrative | 783 | 825 | 2,610 | 2,632 |
| Change in estimate of asset retirement obligation | - | - | - | (48) |
| Total operating expenses | 1,948 | 1,682 | 5,764 | 4,783 |
| Operating loss | (1,339) | (1,389) | (4,359) | (4,443) |
| Non-operating income: | | | | |
| Interest income, net | 7 | 29 | 17 | 89 |
| Change in fair value of warrant derivative liability | - | - | - | 27 |
| Other income | - | - | - | 20 |
| Non-operating income, net | 7 | 29 | 17 | 136 |
| Net loss | (1,332) | (1,360) | (4,342) | (4,307) |
| Preferred stock dividends | (3) | (3) | (8) | (8) |
| Net loss applicable to common shareholders | \$(1,335) | \$(1,363) | \$(4,350) | \$(4,315) |
| Basic and diluted loss per share | \$(0.02) | \$(0.02) | \$(0.08) | \$(0.08) |
| Weighted average shares used in computing net loss per share: | | | | |
| Basic and diluted | 55,100 | 55,017 | 55,058 | 55,015 |

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

IsoRay, Inc. and Subsidiaries
Consolidated Statements of Cash Flows (Unaudited)
(In thousands)

| | Nine months ended March 31, | |
|---|--|----------------|
| | 2018 | 2017 |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| Net loss | \$(4,342) | \$(4,307) |
| Adjustments to reconcile net loss to net cash used by operating activities: | | |
| Depreciation expense | 56 | 50 |
| Loss on equipment disposals | - | 5 |
| Amortization of other assets | 37 | 35 |
| Change in fair value of warrant derivative liability | - | (27) |
| Accretion of asset retirement obligation | 22 | 22 |
| Change in estimate of asset retirement obligation | - | (48) |
| Share-based compensation | 317 | 162 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable, gross | (250) | (249) |
| Inventory | (16) | 54 |
| Prepaid expenses and other current assets | (58) | (44) |
| Accounts payable and accrued expenses | 96 | (104) |
| Accrued protocol expense | 2 | (38) |
| Accrued radioactive waste disposal | (97) | 26 |
| Accrued payroll and related taxes | (33) | (47) |
| Accrued vacation | 2 | 11 |
| Net cash used by operating activities | (4,264) | (4,499) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Additions to property and equipment | (231) | (293) |
| Additions to other assets | - | (151) |
| Proceeds from maturity of certificates of deposit | 4,943 | - |
| Purchases of and interest from certificates of deposit | (4,054) | (87) |
| Net cash provided (used) by investing activities | 658 | (531) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Preferred dividends paid | (11) | (11) |
| Proceeds from sales of common stock, pursuant to exercise of options | 50 | 2 |
| Net cash provided (used) by financing activities | 39 | (9) |
| Net decrease in cash and cash equivalents | (3,567) | (5,039) |
| Cash and cash equivalents, beginning of period | 5,932 | 10,139 |
| CASH AND CASH EQUIVALENTS, END OF PERIOD | \$2,365 | \$5,100 |

Non-cash investing and financing activities:

| | | |
|-------------------------------------|-----|-------|
| Land acquired with accounts payable | \$- | \$198 |
|-------------------------------------|-----|-------|

The accompanying notes are an integral part of these consolidated financial statements.

3

Table of Contents

IsoRay, Inc.

Notes to the Unaudited Consolidated Financial Statements

For the nine months ended March 31, 2018 and 2017

1. Basis of Presentation

The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries referred to herein as “IsoRay” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10-K for the year ended *June 30, 2017*.

The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information *not* to be misleading.

Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented *may not* be indicative of those which *may* be expected for a full year. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2018 will be 0%.

2. New Accounting Pronouncements

In *May 2014*, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) *No. 2014-09* Revenue Recognition, replacing guidance currently codified in Subtopic 605-10 Revenue Recognition-Overall with various SEC Staff Accounting Bulletins providing interpretive guidance. The guidance establishes a new *five* step principle-based framework in an effort to significantly enhance comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. The standard will be effective for the Company in the *first* quarter of its fiscal year 2019, but early adoption is permitted starting in the *first* quarter of fiscal year 2018. The Company intends to adopt the new standard in the *first* quarter of fiscal year 2019 and expects to use the modified retrospective method. The Company has evaluated the impact of the future adoption of

ASU 2014-09 on its consolidated financial statements and does *not* currently expect significant changes in the timing of revenue recognition compared to the existing methodology.

In *July 2015*, the FASB issued ASU No. 2015-11: Inventory. The guidance requires an entity's management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after *December 15, 2016*. Early application is permitted. The ASU became effective for the Company on *July 1, 2017*. This update did *not* have a material impact on the Company's consolidated financial statements upon adoption.

In *November 2015*, the FASB issued an ASU 2015-17 to simplify the balance sheet classification of deferred taxes. This update requires all deferred tax assets and liabilities to be reported as non-current in the consolidated balance sheets. The ASU became effective for the Company on *July 1, 2017*. This update did *not* to have a material impact on the Company's consolidated financial statements upon adoption.

In *February 2016*, the FASB issued ASU 2016-02 Leases (Subtopic 842), which will require lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for annual and interim reporting periods beginning after *December 15, 2018*. Early adoption is permitted. The ASU will be effective for the Company in the *first* quarter of fiscal year 2020. We are currently evaluating the impact of the guidance on the Company's consolidated financial statements.

Table of Contents

In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The update provides guidance on classification for cash receipts and payments related to *eight* specific issues. The update is effective for fiscal years beginning after *December 15, 2017*, and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of implementing this update on the consolidated financial statements.

Other accounting standards that have been issued or proposed by FASB that do *not* require adoption until a future date are *not* expected to have a material impact on the consolidated financial statements upon adoption. The Company does *not* discuss recent pronouncements that are *not* anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

3. Certificates of Deposit

Certificate of Deposit Account Registry Service (CDARS) is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the \$250,000 limit to be fully insured by the Federal Deposit Insurance Corporation (FDIC). That institution utilizes the CDARS system to purchase certificates of deposit at other financial institutions while keeping the investment at each institution fully insured by the FDIC. CDARS held by the Company as of *March 31, 2018* and *June 30, 2017* are as follows (in thousands):

| As of March 31, 2018 | | | | |
|----------------------|---------------|-----------------------|----------------------|---------------------|
| | Under 90 Days | 91 days to six months | Six months to 1 year | Greater than 1 year |
| CDARS | \$1,325 | \$ 825 | \$ - | \$ - |

| As of June 30, 2017 | | | | |
|---------------------|---------------|-----------------------|----------------------|---------------------|
| | Under 90 Days | 91 days to six months | Six months to 1 year | Greater than 1 year |
| CDARS | \$3,039 | \$ - | \$ - | \$ - |

4. Loss per Share

Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does *not* include the impact of any potentially dilutive common stock equivalents. At *March 31, 2018* and *2017*, the calculation of diluted weighted average shares did *not* include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company's net loss position.

Securities *not* considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of *March 31, 2018* and *2017*, were as follows (in thousands):

| | March 31, | |
|-------------------------------------|-----------|-------|
| | 2018 | 2017 |
| Series B preferred stock | 59 | 59 |
| Common stock warrants | 250 | 5 |
| Common stock options | 3,272 | 2,456 |
| Total potential dilutive securities | 3,581 | 2,520 |

5. Inventory

Inventory consisted of the following at *March 31, 2018* and *June 30, 2017* (in thousands):

| | March | June |
|--------------------------|--------|--------|
| | 31, | 30, |
| | 2018 | 2017 |
| Raw materials | \$ 287 | \$ 191 |
| Work in process | 153 | 121 |
| Finished goods | 18 | 11 |
| Total inventory, current | \$ 458 | \$ 323 |

Table of Contents

| | March 31, 2018 | June 30, 2017 |
|------------------------------|----------------------|---------------------|
| Enriched barium, non-current | \$ 347 | \$470 |
| Raw materials, non-current | 48 | 43 |
| Total inventory, non-current | \$ 395 | \$513 |

Inventory, non-current is raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will *not* be consumed within an operating cycle.

On *August 25, 2017*, the Company entered into a Consignment Agreement and related Services Agreement with MedikorPharma-Ural LLC to begin utilizing our enriched barium-130 carbonate inventory beginning in *November 2017*. The Company anticipates obtaining enough Cesium-131 under this arrangement to obtain over *4,000* curies of Cesium-131 over a *ten-year* period but there is *no* assurance as to whether the agreements will be terminated before this full amount is obtained and other supply sources are used, nor is there assurance that the agreements with the *third-party* Cesium-131 suppliers will be executed.

6. Property and Equipment

Property and equipment consisted of the following at *March 31, 2018* and *June 30, 2017* (in thousands):

| | March 31, 2018 | June 30, 2017 |
|-------------------------------|----------------------|---------------------|
| Land | \$366 | \$366 |
| Equipment | 3,806 | 3,776 |
| Leasehold improvements | 4,136 | 4,130 |
| Other ¹ | 568 | 373 |
| Property and equipment | 8,876 | 8,645 |
| Less accumulated depreciation | (7,647) | (7,591) |
| Property and equipment, net | \$1,229 | \$1,054 |

¹ – Represents items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet. Also included at *March 31, 2018* and *June 30, 2017* are costs associated with automation of production processes and advance planning and design work on the Company's new production facility.

7. Share-Based Compensation

The following table presents the share-based compensation expense recognized for stock-based options during the *three* months ended *March 31, 2018* and *2017* (in thousands):

| | Three Months ended March 31, 2018 2017 | |
|-------------------------------------|--|------|
| Cost of product sales | \$10 | \$15 |
| Research and development expenses | 20 | 13 |
| Sales and marketing expenses | 17 | 9 |
| General and administrative expenses | 30 | 3 |
| Total share-based compensation | \$77 | \$40 |

Table of Contents

The following table presents the share-based compensation expense recognized for stock-based options during the *nine* months ended *March 31, 2018* and *2017* (in thousands):

| | Nine Months ended March 31, 2018 2017 | |
|-------------------------------------|---|-------|
| Cost of product sales | \$40 | \$59 |
| Research and development expenses | 58 | 28 |
| Sales and marketing expenses | 50 | 35 |
| General and administrative expenses | 97 | 40 |
| Total share-based compensation | \$245 | \$162 |

As of *March 31, 2018*, total unrecognized compensation expense related to stock-based options was approximately \$622,000 and the related weighted-average period over which it is expected to be recognized is approximately *1.16* years.

A summary of stock options within the Company's share-based compensation plans as of *March 31, 2018* was as follows (in thousands except for exercise prices and terms):

| | Number of Options | Weighted Exercise Price | Weighted Average Contractual Term (Years) | Intrinsic Value |
|-----------------------------|-------------------------|-------------------------------|---|--------------------|
| As of March 31, 2018 | | | | |
| Outstanding | 3,272 | \$.76 | 7.14 | \$ 41 |
| Vested and expected to vest | 3,172 | \$.76 | 7.08 | \$ 41 |
| Vested and exercisable | 1,742 | \$.91 | 5.25 | \$ 41 |

There were *no* stock options exercised during the *three* months ended *March 31, 2018* and *2017*, respectively. The Company's current policy is to issue new shares to satisfy stock option exercises.

There were *15,000* and *10,000* option awards granted with a fair value of approximately \$5,000 and \$4,000 during the *three* months ended *March 31, 2018* and *2017*, respectively.

There were *no* and *22,500* stock option awards which expired during the *three* months ended *March 31, 2018* and *2017*, respectively.

There were *37,500* and *96,432* stock option awards forfeited during the *three* months ended *March 31, 2018* and *2017*, respectively.

There were *82,810* and *6,800* stock options exercised, with approximately *nil* and *\$3,000* of intrinsic value associated with these exercises during the *nine* months ended *March 31, 2018* and *2017*, respectively. The Company's current policy is to issue new shares to satisfy stock option exercises.

There were *90,000* and *20,000* option awards granted with a fair value of approximately *\$38,000* and *\$7,700* during the *nine* months ended *March 31, 2018* and *2017*, respectively.

There were *no* and *303,034* stock option awards which expired during the *nine* months ended *March 31, 2018* and *2017*, respectively.

There were *114,041* and *179,437* stock option awards forfeited during the *nine* months ended *March 31, 2018* and *2017*, respectively.

Table of Contents

8. Commitments and Contingencies

Isotope Purchase Agreement

In *December 2015*, the Company completed negotiations with The Open Joint Stock Company (located in Russia) for the purchase of Cesium-131 manufactured by the Institute of Nuclear Materials. The purchase agreement provided the Company with *one year's* supply of Cesium-131. The original agreement was due to expire on *March 31, 2017*, but in *December 2016* an addendum was signed extending it until *December 31, 2017*. On *October 23, 2017*, the Company, together with The Open Joint Stock Company signed an addendum to the contract to include Cesium-131 manufactured at the Research Institute of Atomic Reactors ("SSC RIAR") and extended it until *December 31, 2018*.

Research and Development - Collaborative Arrangement

On *March 13, 2017*, IsoRay Medical, Inc. (Medical) entered into a Collaborative Development Agreement (CDA) with GammaTile, LLC to further develop a brachytherapy medical device for the treatment of cancerous tumors in the brain and to seek regulatory approval for the new product. As the project manager, Medical will incur all costs in connection with the collaboration project which has been shared equally by both parties as of *November 8, 2016* when they informally began the collaboration. As of *March 31, 2018*, the collaboration is ongoing and we expect it to continue through our fiscal *2018 fourth* quarter. In accordance with ASC 808 "Collaborative Arrangements", this activity is accounted for as a collaborative arrangement and related costs are incurred, shared, and separately stated in connection with a collaborative research and development project. These costs are reported on the financial statements under "Research and development: Collaboration arrangements, net of reimbursement." The Company collaborated with GammaTile LLC in filing applications to the U.S. Food and Drug Administration (FDA) to clear GammaTile™ for clinical use, and a New Technology Add-on Payment (NTAP) to the Center for Medicare and Medicaid Services (CMS) seeking re-imbursement for the GammaTile™ treatment in the in-patient setting. The application with the FDA is ongoing, however, the NTAP was filed in *October 2017*.

During the *three* months ended *March 31, 2018* and *2017*, costs incurred in connection with the CDA were *\$304,000* and *\$322,000*, respectively.

During the *nine* months ended *March 31, 2018* and *2017*, costs incurred in connection with the CDA were *\$509,000* and *\$322,000*, respectively.

As of *March 31, 2018* and *June 30, 2017*, the Company had outstanding receivables from GammaTile LLC of \$73,000 and \$66,000 respectively. These amounts are included in the Prepaid expenses and other current assets on the consolidated balance sheet.

Derivative Complaint related to Shareholder Value

On *September 29, 2016*, David M. Kitley, purportedly on behalf of IsoRay, filed a derivative lawsuit in the United States District Court for the District of Minnesota under the case caption *Kitley v. IsoRay, Inc., Case No. 0:16-cv-03297-DTS*. The complaint named as defendants current and former IsoRay directors Dwight Babcock, Thomas LaVoy, Philip J. Vitale and Michael W. McCormick, alleging that they violated their fiduciary duties to IsoRay in connection with a press release allegedly containing false and misleading statements concerning the results from a peer reviewed study of its Cesium-131 isotope seeds for the treatment of non-small cell lung cancers, thereby artificially inflating the price of IsoRay stock. The complaint sought unspecified damages, in an amount *not* presently determinable, among other forms of relief.

On *November 17, 2016*, IsoRay moved to dismiss the complaint, arguing that plaintiff was *not* entitled to pursue his derivative claims due to his failure to serve a pre-suit demand on IsoRay's board. Rather than respond to the motion to dismiss, plaintiff filed an amended complaint on *January 23, 2017*. The amended complaint alleged the same derivative claims as the original, and added IsoRay director Alan Hoffmann as a defendant. Plaintiff sought an award of damages and an order directing IsoRay to undertake reforms of its corporate governance and internal procedures. IsoRay moved to dismiss the amended complaint on *March 9, 2017*. Plaintiff responded on *April 20, 2017*, and IsoRay replied on *May 17, 2017*. The court heard oral argument on the motion on *August 22, 2017*, and took the matter under advisement at that time. On *October 19, 2017*, the court granted IsoRay's motion to dismiss. The matter is now resolved.

Table of ContentsMedia Advertising Agreement

On *October 3, 2017*, IsoRay entered into a Media Advertising Agreement (the “Agreement”) with AI & J Media Inc., a corporation incorporated in the State of New York (“AI & J”).

Pursuant to the Agreement, AI & J was to introduce IsoRay to potential sources of media, marketing agreements, and/or strategic alliances, including but *not* limited to radio and television media advertising, various media publications, and Internet podcasts. AI & J did *not* promote IsoRay as part of the Agreement; it acted only as a media agent for advertising.

On *December 29, 2017*, IsoRay notified AI&J of its decision to terminate the Agreement between the parties because AI & J's services were *no* longer needed.

As compensation for the services provided prior to termination, IsoRay paid AI & J *\$60,000* and issued AI & J *250,000* warrants upon execution of the Agreement, which vested immediately, entitling AI & J to purchase shares of IsoRay common stock, exercisable on or before *October 3, 2020*, at an exercise price of *\$0.54* per share. See Note 12.

9. Fair Value Measurements

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands):

| Fair Value at March 31, 2018 | | | | |
|------------------------------|---------|---------|---------|------|
| Total | Level 1 | Level 2 | Level 3 | |
| Cash and cash equivalents | \$2,365 | \$2,365 | \$ - | \$ - |

| Fair Value at June 30, 2017 | | | | |
|-----------------------------|---------|---------|---------|------|
| Total | Level 1 | Level 2 | Level 3 | |
| Cash and cash equivalents | \$5,932 | \$5,932 | \$ - | \$ - |

The Company's cash and cash equivalent instruments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

10. Related Party Transactions

During the quarter ended *June 30, 2016*, the Company engaged GO Intellectual Capital, LLC (GO) for marketing services in support of the Company's rebranding effort. Michael McCormick, a member of the Company Board of Directors, is a *1/3* owner of GO. A statement of work was developed defining the scope of the effort and the deliverables to the Company which included a new logo with brand messaging and communication tools including a website, sales presentation tools and a public relations strategy. For the *nine* months ended *March 31, 2017*, the Company paid approximately \$20,000 to GO for its performance of work related to the agreed upon statement of work. *No* such services were provided in the *nine* months ended *March 31, 2018*.

11. Concentrations of Credit and Other Risks

One group of customers, facilities or physician practices has revenues that aggregate to greater than *10%* of total Company product sales:

| Facility | Nine months ended | |
|---|-------------------|----------------|
| | March 31, 2018 | March 31, 2017 |
| El Camino Hospital of Los Gatos, Fremont Surgery Center & other facilities ¹ | 24.23% | 22.76% |

¹ – This group of facilities individually each comprise less than *10%* of total Company product sales. They are serviced by the same physician group, *one* of whom is our Medical Director.

Table of Contents

The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary.

12. Shareholders' Equity*Warrants*

On *October 3, 2017*, the Company entered into a Media Advertising Agreement with Al & J Media Inc. ("Al & J"). As part of the compensation for the services, Al & J received 250,000 warrants upon execution of the Agreement, which vested immediately, entitling Al & J to purchase shares of IsoRay common stock, exercisable on or before *October 3, 2020*, at an exercise price of *\$0.54* each. These warrants, using the Black-Scholes model, resulted in approximately *\$72,000* of share based compensation during the *nine* months ended *March 31, 2018*. On *December 29, 2017*, the Company notified Al & J of its decision to terminate the Media Advertising Agreement.

The key assumptions used in the Black-Scholes valuation model to calculate the fair value of the warrants are as follows:

| | | |
|--------------------------|-----------------------|---|
| | October 3, 2017 | |
| Grant date fair value | \$0.2874 | |
| Options issued | 250,000 | |
| Exercise price | \$0.54 | |
| Expected term (in years) | 3 | |
| Risk-free rate | 1.62 | % |
| Volatility | 81.66 | % |

The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices by category.

| | | |
|---------------------------------|----------|--|
| | | Weighted average exercise price |
| | Warrants | |
| Outstanding as of June 30, 2017 | - | \$ - |

Edgar Filing: IsoRay, Inc. - Form 10-Q

| | | |
|----------------------------------|---------|---------|
| Warrants issued | 250,000 | \$ 0.54 |
| Outstanding as of March 31, 2018 | 250,000 | \$ 0.54 |

The following table summarizes additional information about the Company's common warrants outstanding as of *March 31, 2018*:

| Number of Warrants | Exercise Price ¹ | Expiration Date |
|--------------------|-----------------------------|-----------------|
| 250,000 | \$ 0.54 | October 2020 |

¹ – Exercise prices have been rounded to the nearest whole cent.

Table of Contents

ITEM 2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Caution Regarding Forward-Looking Information

In addition to historical information, this Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA.

All statements contained in this Form 10-Q, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future revenue, economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under Item 1A - Risk Factors below that may cause actual results to differ materially.

Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company’s views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Critical Accounting Policies and Estimates

The discussion and analysis of the Company’s financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, management

evaluates past judgments and estimates, including those related to bad debts, inventories, accrued liabilities, derivative liabilities and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies and related risks described in the Company's annual report on Form 10-K as filed with the SEC on September 28, 2017 are those that depend most heavily on these judgments and estimates. As of March 31, 2018, there had been no material changes to any of the critical accounting policies contained therein.

Overview

IsoRay, Inc. is a brachytherapy device manufacturer with FDA clearance and CE marking for a single medical device that can be delivered to the physician in multiple configurations as prescribed for the treatment of cancers in multiple body sites. The Company manufactures and sells this product as the Cesium-131 brachytherapy seed.

The brachytherapy seed utilizes Cesium-131, with a 9.7 day half-life, as its radiation source. The Company believes that it is the unique combination of the short half-life and the energy of the Cesium-131 isotope that is yielding the beneficial treatment results that have been published in peer reviewed journal articles and presented in various forms at conferences and tradeshow.

The Company has distribution agreements outside of the United States through its subsidiary IsoRay International LLC. These distributors are responsible for obtaining regulatory clearance to sell the Company's products in their territories, with the support of the Company. As of the date of this report, the Company had distributors in Italy and the Russian Federation, with approximately \$35,000 in reported revenues in the nine months ended March 31, 2018.

Table of Contents**Results of Operations****Three months ended March 31, 2018 and 2017 (in thousands):**

| | Three months ended March 31, | | | | |
|---|------------------------------|----------|---------|-------|----------------|
| | 2018 | | 2017 | | 2018 - 2017 |
| | Amount | % (a) | Amount | % (a) | % Change |
| Product sales, net | \$1,573 | 100 | \$1,282 | 100 | 23 |
| Cost of product sales | 964 | 61 | 989 | 77 | (3) |
| Gross profit / (loss) | 609 | 39 | 293 | 23 | 108 |
| Operating expenses: | | | | | |
| Research and development expenses - proprietary | 317 | 20 | 166 | 13 | 91 |
| Research and development expenses – collaboration agreement, net of reimbursement | 156 | 10 | 161 | 13 | (3) |
| Sales and marketing expenses | 692 | 44 | 530 | 41 | 31 |
| General and administrative expenses | 783 | 50 | 825 | 64 | (5) |
| Total operating expenses | 1,948 | 124 | 1,682 | 131 | 16 |
| Operating loss | (1,339) | (85) | (1389) | (108) | (4) |

(a) Expressed as a percentage of product sales, net

Nine months ended March 31, 2018 and 2017 (in thousands):

| | Nine months ended March 31, | | | | |
|---|-----------------------------|-------|---------|-------|----------------|
| | 2018 | | 2017 | | 2018 - 2017 |
| | Amount | % (a) | Amount | % (a) | % Change |
| Product sales, net | \$4,320 | 100 | \$3,391 | 100 | 27 |
| Cost of product sales | 2,915 | 67 | 3,051 | 90 | (4) |
| Gross profit / (loss) | 1,405 | 33 | 340 | 10 | 313 |
| Operating expenses: | | | | | |
| Research and development expenses - proprietary | 914 | 21 | 488 | 14 | 87 |
| Research and development expenses – collaboration agreement, net of reimbursement | 260 | 6 | 161 | 5 | 61 |
| Sales and marketing expenses | 1,980 | 46 | 1,550 | 46 | 28 |

Edgar Filing: IsoRay, Inc. - Form 10-Q

| | | | | | |
|-------------------------------------|---------|-------|---------|-------|--------|
| General and administrative expenses | 2,610 | 60 | 2,632 | 77 | (1) |
| Change in estimate of ARO | - | - | (48) | (1) | (100) |
| Total operating expenses | 5,764 | 133 | 4,783 | 141 | 21 |
| Operating loss | (4,359) | (101) | (4,443) | (131) | (2) |

(a) Expressed as a percentage of product sales, net

Product Sales

Changes in sales personnel and implementation of a revitalized sales and marketing strategy in the third quarter of fiscal 2017 has resulted in positive sales growth in the third quarter of fiscal 2018 when compared to the prior fiscal year's third quarter. Ongoing training and support of new sales personnel has led to not only new accounts but also reconnecting with and receiving orders from prior accounts.

Table of Contents**Three months ended March 31, 2018 and 2017 (in thousands):**

| | Three months ended March 31, | | | | |
|------------------------|------------------------------|-----|---------|-----|----------------|
| | 2018 | | 2017 | | 2018 - 2017 |
| | Amount | % | Amount | % | % |
| | (a) | (a) | (a) | (a) | Change |
| Prostate brachytherapy | \$1,304 | 83 | \$1,124 | 88 | 16 |
| Other brachytherapy | 269 | 17 | 158 | 12 | 70 |
| Product sales, net | 1,573 | 100 | 1,282 | 100 | 23 |

(a) Expressed as a percentage of product sales, net

Nine months ended March 31, 2018 and 2017 (in thousands):

| | Nine months ended March 31, | | | | |
|------------------------|-----------------------------|-----|---------|-----|---------------|
| | 2018 | | 2017 | | 2018- 2017 |
| | Amount | % | Amount | % | % |
| | (a) | (a) | (a) | (a) | Change |
| Prostate brachytherapy | \$3,703 | 86 | \$2,979 | 88 | 24 |
| Other brachytherapy | 617 | 14 | 412 | 12 | 50 |
| Product sales, net | 4,320 | 100 | 3,391 | 100 | 27 |

(a) Expressed as a percentage of product sales, net

Prostate Brachytherapy

During the quarter ended March 31, 2018, the Company had a full sales team in place contributing to the increase in sales. Also, website improvements and significant investments in product support literature, social media and public relations are increasing the awareness of the Company in the prostate brachytherapy treatment markets providing the Company opportunities to develop new customers and reconnect with past customers.

Management believes growth in prostate brachytherapy revenues will be the result of physicians, payers, and patients increasingly considering overall brachytherapy treatment advantages including costs, better treatment outcomes and improvement in the quality of life for patients, when compared with non-brachytherapy treatments.

During the nine months ended March 31, 2018, approximately \$35,000 of reported revenues originated from the international market.

Management believes increased pressure to deliver effective healthcare in both terms of outcome and cost drove treatment options, and accordingly drove the Company's prostate revenues, in the quarter ended March 31, 2018.

Other Brachytherapy

Other brachytherapy includes, but is not limited to, brain, lung, head/neck, and gynecological treatments. Initial applications for these other brachytherapy treatments are primarily used in recurrent cancer treatments or salvage cases that are generally difficult to treat aggressive cancers where other treatment options are either ineffective or unavailable.

These other brachytherapy treatments continue to be subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of physicians. This causes the revenue created by these types of treatment applications to be more volatile and vary significantly from quarter to quarter. This volatility resulted in the increase from the prior year.

Table of Contents

Cost of product sales

Cost of product sales consists primarily of the costs of manufacturing and distributing the Company's products.

Contributing to the three and nine months ended March 31, 2018 and 2017 comparisons were decreases attributed to cost savings initiatives that resulted in lower procurement costs of goods and services. Some costs shifted in the three and nine months ended March 31, 2018 as compared to the same periods in fiscal 2017 to research and development and property and equipment, net from cost of product sales as employees performed research and development work as well as worked on the automation projects. Also, reduced staffing costs were realized with decreased head count. These decreases were partially offset by an increase in supply of isotope from the University of Missouri Research Reactor ("MURR") which increased total cost of product sales but resulted in lower supply cost per curie of Cesium-131 obtained from MURR.

Research and development

Research and development – proprietary

Proprietary research and development consists primarily of employee and third-party costs related to research and development activities.

Contributing to the three months ended March 31, 2018 and 2017 and the nine months ended March 31, 2018 and 2017 proprietary research and development comparison were increases associated with participation in new protocols, device development activities, as well as a reallocation of employee costs from cost of product sales as those employees performed work on research and development projects.

Research and development – collaborative arrangement

Collaboration arrangement related costs are incurred, shared, and separately stated in connection with a Collaborative Development Agreement (CDA) with GammaTile, LLC.

During the three months ended March 31, 2018 and 2017, costs incurred in connection with the CDA were \$304,000 and \$322,000, respectively.

During the nine months ended March 31, 2018 and 2017, costs incurred in connection with the CDA were \$509,000 and \$322,000, respectively.

Sales and marketing expenses

Sales and marketing expenses consist primarily of the costs related to the internal and external activities of the sales, marketing and customer service functions of the Company. As the Company increasingly focuses on improving sales, the cost associated with marketing and greater staffing continues to increase.

Staffing differences are a major factor in the cost comparison for the three months ended March 31, 2018 and 2017 as open positions in the quarter ended March 31, 2017 were filled in periods prior to the quarter ended March 31, 2018 with increased salaries and increased travel costs. Due to increased sales, there were also increases in incentive compensation.

Contributing to the nine months ended March 31, 2018 and 2017 comparison were increased advertising and public relations costs as part of the revitalized marketing plan. Staffing differences are a major factor in the cost comparison as open positions in the nine months ended March 31, 2017 were filled in periods prior to the quarter ended March 31, 2018 with increased salaries and travel costs. Due to increased sales, there were also increases in incentive compensation.

Table of Contents**General and administrative expenses**

General and administrative expenses consist primarily of the costs related to the executive, human resources/training quality assurance/regulatory affairs, finance, and information technology functions of the Company.

Contributing to the three months ended March 31, 2018 and 2017 comparison were significant reductions in legal fees, decreases to payroll as a result of the re-organization of the finance department with reduced head count, decreased consulting fees, and public company related expenses. These cost decreases were partially offset in the three months ended March 31, 2018 by increased share-based compensation and bonus expenses, and increased travel costs.

Contributing to the nine months ended March 31, 2018 and 2017 comparison were cost decreases from the prior year. Those include significant decreases to legal expenses, decreases to payroll as a result of the re-organization of the finance department with reduced head count, decreased consulting fees, lower audit and bank fees, and seminars, conference, and training expenses. These cost decreases were partially offset in the nine months ended March 31, 2018 by increases associated with share-based compensation, bonus expense, investor relations fees, state taxes, and employment hiring expenses related to the hiring of the Company's Controller.

Liquidity and capital resources

The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has historically financed its operations through selling equity to investors. During the nine month periods ended March 31, 2018 and 2017, the Company used existing cash reserves to fund its operations and capital expenditures (in thousands except current ratio):

| | Nine months ended March 31, | |
|--|--------------------------------|-----------|
| | 2018 | 2017 |
| Net cash used by operating activities | \$(4,264) | \$(4,499) |
| Net cash provided (used) by investing activities | 658 | (531) |
| Net cash provided (used) by financing activities | 39 | (9) |
| Net decreases in cash and cash equivalents | \$(3,567) | \$(5,039) |

As of
March June
31, 30,

| | 2018 | 2017 |
|-----------------|---------|---------|
| Working capital | \$5,202 | \$9,185 |
| Current ratio | 5.63 | 9.30 |

Cash flows from operating activities

Net cash used by operating activities in the nine months ended March 31, 2018 was primarily due to a net loss of approximately \$4.34 million, net of approximately \$432,000 in adjustments for non-cash activity such as depreciation and amortization expense, ARO accretion, and share-based compensation. Changes in operating assets and liabilities used approximately \$354,000 to fund operating activities; Increases in accounts receivable, inventory, and prepaid expenses and other current assets, along with decreases in accrued radioactive waste disposal and accrued payroll and related taxes were partially offset by an increase in accounts payable and accrued expenses.

Cash flows from investing activities

Investing activities for the nine months ended March 31, 2018 consisted of transactions related to the purchase of fixed assets, including automation of production processes, as well as the purchase and subsequent maturity of certificates of deposit. Management will continue to invest in technology and machinery that improves and streamlines production processes and to invest maturing certificates of deposit in low-risk investment opportunities that safeguard assets and provide greater assurance those resources will be liquid and available for business needs as they arise.

Table of Contents

Cash flows from financing activities

Financing activities in the nine months ended March 31, 2018 included payment of preferred dividends and proceeds of sales of common stock through option exercises.

Projected 2018 Liquidity and Capital Resources

Operating activities

Management forecasts that current cash and cash equivalents along with certificates of deposit will be sufficient to meet projected operating cash needs for the remainder of fiscal 2018 and into the first half of fiscal 2019. Assuming no extraordinary expenses occur (whether operating or capital), if management is successful at implementing its strategy of renewed emphasis on driving the consumer to the prostate market, meets or exceeds its annual growth targets of twenty percent increase in revenue in fiscal 2018 and this annual growth continues, the Company anticipates reaching cashflow break-even in three to five years. Although the Company did not reach that target of twenty percent increased revenue in the first quarter of fiscal 2018, that target was surpassed in the second and third quarters and the Company is continuing to project revenue growth in fiscal 2018 of at least twenty percent over fiscal 2017. There is no assurance that targeted sales growth will materialize over the next three to five years. However, management is encouraged by the results for the nine months ended March 31, 2018 and with the depth and experience of its restructured sales team.

Capital expenditures

Management has completed the design of a future production and administration facility. If financing is obtained and the facility constructed, it is believed that the new facility will have non-cash depreciation cost equal to or greater than the monthly rental cost of the current facility.

Management is reviewing and implementing changes in all aspects of production operations (including process automation), research and development, sales and marketing, and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems, and personnel are available to support and drive product sales.

During the nine months ended March 31, 2018, the Company invested approximately \$175,000 in the automation of production processes, resulting in the completion of three pieces of equipment. Each have been received, tested and evaluated, and were placed in service in the nine months ended March 31, 2018. One additional machine has been received and is currently being tested. Beginning in fiscal 2017 and continuing through March 31, 2018, the Company has invested approximately \$476,000 in these automation projects and management is expecting to invest approximately \$360,000 more over the next 14 months on the remaining projects. This investment is designed to allow the Company to significantly increase the output of Cesium-131 brachytherapy seeds, while allowing the Company to decrease the labor costs related to seed production and also improving the overall safety of our operations.

Financing activities

There was no material change in the use of proceeds from our public offering as described in our final prospectus supplement filed with the SEC pursuant to Rule 424(b) on March 24, 2014. Through March 31, 2018, the Company had used the net proceeds raised through the March 2014 offering as described in the public offering. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.

On August 25, 2015, the Company filed a registration statement on Form S-3 to register securities up to \$20 million in value for future issuance in our capital raising activities. The registration statement became effective on November 19, 2015, and the SEC file number assigned to the registration statement is 333-206559.

The Company expects to finance its future cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing shareholders. Management anticipates that if it raises additional financing that it may be at a discount to the market price and if so it will be dilutive to shareholders.

Table of Contents

The Company's common stock is currently listed on the NYSE American stock exchange, which will consider delisting a company's securities if, among other things, a company fails to maintain minimum stockholder's equity. With the Company's existing cash reserves, we believe we will not be able to maintain our listing on the NYSE American unless we raise capital in the next three months assuming we maintain our projected budgeted expenses and contemplated level of revenues.

Other Commitments and Contingencies

The Company presented its other commitments and contingencies in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017. There have been no material changes outside of the ordinary course of business in those obligations during the quarter ended March 31, 2018 other than those previously disclosed in Note 8 to the interim financial statements contained in this Form 10-Q.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and on various other factors the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results could therefore differ materially from those estimates if actual conditions differ from our assumptions.

During the quarter ended March 31, 2018, there have been no changes to the critical accounting policies and estimates, as discussed in Part II, Item 7 of our Form 10-K for the year ended June 30, 2017.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to the disclosure in the “Quantitative and Qualitative Disclosures about Market Risk Factors” section of our Annual Report on Form 10-K for the year ended June 30, 2017.

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-14(c) and 15d-14(c) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of March 31, 2018. Based on that evaluation, our principal executive officer and our principal financial officer concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures is designed to provide a reasonable level of assurance that the objectives of the system will be met.

Table of Contents

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

The Company is not involved in any material legal proceedings as of the date of this Report.

ITEM 1A – RISK FACTORS

A description of the risk factors associated with our business is included under “Risk Factors” contained in Part I, Item 1A of our Form 10-K for the year ended June 30, 2017, and is incorporated herein by reference. There have been no material changes in our risk factors since such filing, except for the following:

We Rely Heavily On Five Customers

For the nine months ended March 31, 2018, approximately 46% of the Company’s revenues were dependent on five customers with approximately 24% being generated by one group of customers. The loss of any of these customers would have a material adverse effect on the Company’s revenues which may not be replaced by other customers particularly as these customers are in the prostate sector which is facing substantial competition from other treatments.

We Will Need Additional Capital In The Next Three Months To Maintain Our NYSE American Listing And For Acquisitions And Expansion Into Other Markets.

Our common stock is currently listed on the NYSE American stock exchange which will consider delisting a company's securities if, among other things, a company fails to maintain minimum stockholder's equity. With our existing cash reserves we believe we will not be able to maintain our listing on the NYSE American unless we raise capital in the next three months assuming we maintain our projected budgeted expenses and contemplated level of revenues. In the event that our common stock is delisted from the NYSE American, trading, if any, in the common stock would be conducted in the over-the-counter market. As a result, our shareholders would likely find it more difficult to dispose of, or to obtain accurate quotations as to the market value of, our common stock. We may also need to raise capital for strategic acquisitions or expansion into other markets and there is no assurance management will not pursue this additional capital if available.

Table of Contents

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5 – OTHER INFORMATION

None

ITEM 6. EXHIBITS

Exhibits:

- 10.1 Manufacturing and Supply Agreement, dated January 3, 2018, between IsoRay Medical, Inc. and GT Medical Technologies, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on January 8, 2018.
- 10.2 Collaborative Development Agreement, dated effective as of March 13, 2017, between IsoRay Medical, Inc. and GammaTile, LLC, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on January 8, 2018.
- 31.1* Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
- 31.2* Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer

32** Section 1350 Certifications

101.INS* XBRL Instance Document

101.SCH* XBRL Taxonomy Extension Schema Document

101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF* XBRL Taxonomy Extension Definition Linkbase Document

101.LAB* XBRL Taxonomy Extension Label Linkbase Document

101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 4, 2018

ISORAY, INC., a Minnesota corporation

/s/ Thomas C. LaVoy
Thomas C. LaVoy
Chief Executive Officer
(Principal Executive Officer)

/s/ Mark J. Austin
Mark J. Austin
Controller
(Principal Financial and Accounting Officer)